Latitude gradient influences the age of onset of rheumatoid arthritis : a worldwide survey by Ramos-Remus, Cesar et al.
ORIGINAL ARTICLE
Latitude gradient influences the age of onset of rheumatoid
arthritis: a worldwide survey
GEO-RA Group
Received: 10 October 2016 /Accepted: 7 November 2016 /Published online: 19 December 2016
# International League of Associations for Rheumatology (ILAR) 2016
Abstract The age of onset of rheumatoid arthritis (RA) is an
important outcome predictor. Northern countries report an age
of RA onset of around 50 years, but apparently, variability
exists across different geographical regions. The objective of
the present study is to assess whether the age of onset of RA
varies across latitudes worldwide. In a proof-of-concept cross-
sectional worldwide survey, rheumatologists from preselected
cities interviewed 20 consecutive RA patients regarding the
date of RA onset (RAO, when the patient first noted a swollen
joint). Other studied variables included location of each city,
rheumatologist settings, latitudes (10° increments, south to
north), longitudes (three regions), intracountry consistency,
and countries’ Inequality-adjusted Human Development
Index (IHDI). Data from 2481 patients (82% females) were
obtained from 126 rheumatologists in 77 cities of 41 coun-
tries. Worldwide mean age of RAO was 44 ± 14 years (95%
CI 44–45). In 28% of patients, RA began before age 36 years
and before age 46 years in 50% of patients. RAO was 8 years
earlier around the Tropic of Cancer when compared with
northern latitudes (p < 0.001, 95% CI 3.5–13). Multivariate
analysis showed that females, western cities, and latitudes
around the Tropic of Cancer are associated with younger age
of RAO (R2 0.045, p < 0.001). A positive correlation was
found between the age of RAO and IHDI (r = 0.7, p < 0.01,
R2 0.5). RA often begins at an early age and onset varies
across latitudes worldwide. We postulate that countries’
developmental status and their geographical and geomagnetic
location influence the age of RAO.
Keywords Age of onset . Environmental .
Geoepidemiology . Inequality . Pollution . Rheumatoid
arthritis
Introduction
Rheumatoid arthritis (RA) is a disease of unknown cause and
variable clinical presentation. Its prevalence and incidence
vary across populations [1–3] and time [4–6]. Patients with
RA may have a variable course, and their response to treat-
ment is oftentimes unpredictable. Because of this variability,
RA has been described as one of modern medicine’s greatest
enigmas [7].
The complete etiologic picture of this disease remains un-
clear because the genetic contribution to RA has been estimat-
ed to be 12–60% [8, 9], and environmental factors contribute
to up to half of the variation in disease susceptibility [10].
Variations in the reported figures on genetic and environmen-
tal factors across populations can be partially explained by
differences in study design, the time when studies were per-
formed, and that the data often come from historical studies
that are restricted to specific regions or ethnic groups.
Nevertheless, it is recognized that there are differences in the
rates of occurrence of RA between countries and areas of the
world [3].
The age of RA onset (RAO) is recognized as one of the
most important predictors of disease outcome [11]. When RA
starts at an early age, the economic burden imposed upon the
patient, their family, and health services may be devastating.
However, variability in the age of RAO is often neglected in
studies of RA patterns. Some reports involving patients of
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European descent from developed countries found that the
mean age of RAO is around 50 years [2, 12–14] with epide-
miologic studies from these countries consistently reporting
incidence rates that increase with age into the 70s [1].
Conversely, some studies from African and Asian countries
have observed a significantly earlier peak in the mean age of
RAO, which can be as young as the 20s or 30s [1]. Significant
variations in the age of RAO have been reported in regional
studies at different latitude gradients, both in terms of the
mean age of onset and the frequency distribution by age
groups [15, 16].
Latitude gradients have been used in geoepidemiology as a
surrogate to study the influence of environment on disease
incidence and risks across different geographic areas, so as
to generate hypotheses for further investigation [17]. For ex-
ample, diseases such as systemic lupus erythematosus, derma-
tomyositis, and Crohn’s disease are geographically associated
with northern latitudes [17].
The objective of this proof-of-concept cross-sectional sur-
vey was to assess whether the age of RAO varies across lati-
tudes worldwide.
Subjects and methods
In a proof-of-concept survey, rheumatologists working at
preselected cities around the world interviewed consec-
utive RA patients regarding their disease onset. Major
cities were selected by 15° quadrants (latitude and lon-
gitude) worldwide. Rheumatologist contact information
for these cities was obtained using regional or local
rheumatology association open databases, the web site
of the US National Library of Medicine (PubMed), and
direct recommendation from selected rheumatologists.
An individualized invitation letter, which included infor-
mation about the study but not its hypothesis, was sent
electronically to each identified rheumatologist. A reply
confirming the rheumatologists’ interest in participating
and confirmation of whether they treated RA patients
and were board certified in rheumatology, the type of
clinical practice (private, university, or other), and the
city and country where the rheumatologist worked was
requested. No compensation was offered. A second elec-
tronic communication, with detailed instructions that in-
cluded guidelines on how to gather patient information
in the data log sheet format, was sent to rheumatologists
who agreed to participate. Participants were to provide
data by directly interviewing 20 consecutive RA pa-
tients as per the 1987 criteria of the American
Rheumatism Association [18]. This information was
limited to nonsensitive data, in compliance with local
regulations, and included nontraceable patient identifica-
tion (e.g., consecutive numbers, letters, or initials), date
of birth (month and year), sex, date of RA diagnosis
(month and year), and date of RAO, defined as the
month and year when the patient first noticed a swollen
joint.
Data from data log sheets were extracted by two medical
students, and the precise latitude and longitude of each city
were obtained using Google Earth (Google Inc., Mountain
View, CA, USA). For cases in which the data log sheet in-
cluded errors or inconsistencies for up to three patients, the
participating rheumatologist was asked to review the data. If
there were four or more patients with inconsistent data or
submitted data from less than 18 patients, the complete set
was excluded; no substitutions were allowed. Summary data
and manuscript drafts were shared with all participants.
Statistical analysis
Data handling was based on the following assumptions:
(a) rheumatologists would have easy access to 20 RA
patients in their clinical practice over a short period of
time, to assure their compliance; (b) comparing data
from two or more rheumatologists in the same city
would allow us to assess the intracity consistency of
the main variable (age of RAO) using nonparametric
Mann–Whitney U or Kruskal–Wallis tests; and (c) com-
paring data from two or more cities located at the same
latitude in each country would allow us to assess
intracountry consistency of the main variable using
parametric tests (Student’s t test or one-way ANOVA).
The age of RAO was examined as both a continuous
variable and a categorical variable (age groups, 10-year
increments).
Differences in age of RAO according to latitudes
worldwide (10° increments, south to north) were examined
using one-way ANOVA for continuous variables (with a
post hoc Schaffé for multiple comparisons), whereas a
Pearson’s chi-square or Fisher’s exact test was used for
categorical variables. Thereafter, the world map was arbi-
trarily divided by longitudes into three regions: region 1
(30° W to 134° W) that includes countries of the
Americas; region 2 (29° W to 104° E) that includes coun-
tries of Europe, Africa, and Western Asia; and region 3
(105° E to 180° E) that includes countries of East Asia
and Oceania. This division was made to assess whether
significant differences in the age of RAO, detected accord-
ing to latitudes worldwide, persisted by region (using one-
way ANOVA and Pearson’s chi-square or Fisher’s exact
test). A p of ≤0.05 was set as the level of statistical
significance, and confidence intervals were reported at
95% (95% CI).
Stepwise multiple linear regression analysis was performed
to assess the effects of sex (binary), northern cities (binary),
western cities (binary, from the Greenwich parallel), cities
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grouped per longitude (categorical variable, three regions),
and cities grouped per latitude code (categorical variable, each
10°) on age of RAO. A backward regression was run for all
significant variables (p < 0.1) identified by univariate analysis.
After reviewing the results, a post hoc analysis was per-
formed to explore whether the age of RAO is correlated with
the developmental status of participating countries (Pearson’s
correlation coefficient). The countries’ developmental status
was obtained from the United Nations Development
Programme report [19] on the 2015 Human Development
Index (HDI) (years 2010–2014) and on the Inequality-
adjusted HDI (year 2014).
This being a nonintervention study, and the collected infor-
mation precludes individual patient identification (nonsensi-
tive data), no informed consent was required as per local reg-
ulations at each site.
Results
Figure 1 shows the distribution of rheumatologists invited to
participate and those who accepted our invitation. Figure 2
shows the distribution of the mean age of RAO by participat-
ing country, with the number of sites (rheumatologists) and
cities per country. We obtained data of 2481 patients (82%
females) from 126 rheumatologists in 77 cities of 41 countries.
Table 1 shows the mean age of RAO and the frequency
distribution by age group according to latitude in 10° intervals
from south to north. The worldwide overall mean age of RAO
was 44.4 ± 14 years (95% CI 44–45). The overall frequency
distribution by age group shows that 28% of patients had an
RAO before the age of 36 years and between the ages of 16
and 45 years in 50% of patients. Analysis of age of RAO by
latitude showed significant differences in both, as mean and as
distribution by age groups. Age of RAO for latitude code 8
(20° N to 29° N) was on average 8, 8, 5, and 6 years younger
when compared with latitude codes 11, 10, 3, and 2, respec-
tively (p < 0.001, 95% CI for differences of 3.5–13, 2–13,
0.1–10, and 2–10 years, respectively). Latitude codes 8 and
9 (around the Tropic of Cancer) had a higher proportion of
patients with an RAO before age 35 years compared with
northern or southern latitudes (p < 0.001). Intracity variability
could be assessed in 29 (38%) cities, and consistency was
confirmed in 79% of them (supplementary Table 1).
Intracountry variability could be assessed for 19 (46%) coun-
tries, and consistency was ascertained in 16 (84%)
(supplementary Table 2).
The results of subanalysis by region (longitudes) are
shown in Table 2 as the mean age of RAO and in
Table 3 as the frequency distribution by age group, both
by latitude in 10° intervals south to north. Similar
trends were observed in region 1 (the Americas), where
12 countries participated and provided data on a total of
1062 patients. No rheumatologists from the USA replied
to our electronic communications. The overall mean age
of RAO was 44 ± 14 years (95% CI 43–45). Disease
onset was on average 8 and 14.5 years younger for
latitude code 8 compared with northern latitude codes
11 and 10, respectively (p < 0.01), and 7 years younger
than southern latitude code 2 (31°–40° S) (p = 0.01).
The frequency distribution by age group showed that in
latitude code 8, nearly half of patients had RAO before
the age of 36 years, which was significantly different
when compared with latitude codes 2 (24.8%) and 6
(27.8%) (p < 0.001). In region 2 (Europe, Africa, and
Western Asia), 24 countries participated, yielding data
on 1126 total patients. The overall mean age of RAO
was 44 ± 14 years (95% CI 43–45). For latitude code 8,
RAO was on average 8.5 and 7.5 years younger when
compared with northern latitude codes 11 and 10, re-
spectively (p < 0.01). For latitude codes 8 and 9, there
were a significantly higher proportion of patients with
RAO before age 36 years compared with latitudes 10
and 11 (p = 0.01). However, there is no land in latitude
code 1 (>40° S). In addition, in latitude code 4 (11° S–
Invited: 
Rheumatologists: 
529 
Countries: 55 
Cities: 186 
Final participants: 
-    126 Rheumatologists 
-      41 Countries 
-      77 Cities 
- 2,481 Patients 
Accepted participation:
162 
Sent data Log Sheet: 
- 128 Rheumatologists 
- 2,517 patients  
Declined participation:
7 
Did not reply: 321 
Wrong Address: 39 
Further declined 
participation: 8 
Did not send data:
26 
Incomplete or discrepant 
information: 2  
Fig. 1 Flow chart of study participants (rheumatologists, countries, and
cities)
Clin Rheumatol (2017) 36:485–497 487
20° S), we were unable to contact rheumatologists in
Senegal, Guinea, Niger, Ethiopia, and Sudan. The num-
ber of patients varied per country, yielding a broad 95%
CI for latitude codes 3 and 5. In region 3 (East Asia
and Oceania), five countries participated and provided
data on 293 patients. We were unable to contact
Fig. 2 Mean age of onset of rheumatoid arthritis distributed by participating country, number of cities (C), number of sites (S) (rheumatologists), and
number of patients (P)
Table 1 Worldwide distribution of mean age of onset of rheumatoid arthritis (RA) and frequency distribution by age group per every 10° of latitude,
south to north
Latitude, code (location) Patients N= Age of onset of RA,
mean ± SD (years)
(95% CI)
Age groups (years) n (%)**
16–25 26–35 36–45 46–55 56–65 >65
1 (>40° S) 96 45 ± 14 (42.5 to 48) 4 (4.2%) 22 (22.9%) 23 (24%) 23 (24%) 13 (13.5%) 11 (11.5%)
2 (31° to 40° S) 473 46 ± 14 (44 to 47) 32 (6.8%) 80 (16.9%) 125 (26.4%) 113 (23.9%) 84 (17.8%) 39 (8.2%)
3 (21° to 30° S) 213 45 ± 14 (43 to 47) 19 (8.9%) 32 (15%) 50 (23.5%) 58 (27.2%) 37 (17.4%) 17 (8%)
4 (11° to 20° S) 80 45 ± 14.5 (41.5 to 48) 8 (10%) 14 (17.5%) 16 (20%) 22 (27.5%) 12 (15%) 8 (10%)
5 (1° to 10° S) 138 43 ± 13 (41 to 45) 15 (10.9%) 24 (17.4%) 34 (24.6%) 40 (29%) 19 (13.8%) 6 (4.3%)
6 (0° to 9° N) 158 44 ± 15 (42 to 46.5) 21 (13.3%) 20 (12.7%) 40 (25.3%) 41 (25.9%) 24 (15.2%) 12 (7.6%)
7 (10° to 19° N) 316 44 ± 13 (42 to 45) 33 (10.4%) 54 (17.1%) 61 (19.3%) 107 (33.9%) 49 (15.5%) 12 (3.8%)
8 (20° to 29° N) 389 40 ± 12* (39 to 41) 41 (10.5%) 105 (27%) 104 (26.7%) 99 (25.4%) 29 (7.5%) 11 (2.8%)
9 (30° to 39° N) 193 43 ± 15 (41 to 45) 18 (9.3%) 48 (24.9%) 43 (22.3%) 46 (23.8%) 22 (11.4%) 16 (8.3%)
10 (40° to 49° N) 153 48 ± 14 (45 to 50) 6 (3.9%) 31 (20.3%) 30 (19.6%) 37 (24.2%) 30 (19.6%) 19 (12.4%)
11 (>50° N) 272 48 ± 15 (46 to 50) 18 (6.6%) 44 (16.2%) 52 (19.1%) 55 (20.2%) 63 (23.2%) 40 (14.7%)
Total 2481 44 ± 14 (44 to 45) 215 (8.7%) 474 (19.1%) 578 (23.3%) 641 (25.8%) 382 (15.4%) 191 (7.7%)
*Latitude code 8 is significantly different compared with latitude codes 2, 3, 10, and 11; p < 0.001
**Significant differences of age groups by latitudes, p < 0.001
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rheumatologists in latitudes 4 to 6 (the Republic of
Indonesia and Papua New Guinea) or latitudes 10 and
11 (the Kuril Islands and the Kamchatka Peninsula). No
significant differences were found in this region for
mean age of RAO and frequency distribution by age
group, probably incurring in a type II error.
The final model in the stepwise multiple linear regression
analysis included sex, latitude coded groups, and western cit-
ies. A significant regression equation was found (F (12,
2468) = 9.72, p < 0.001), with an R2 of 0.045. The age of
RAO was significantly younger among females and patients
from western cities; age of RAO was older at northern lati-
tudes (>50° N) (Table 4). We did not find significant differ-
ences between other variables, such as rheumatologist practice
type or the number of years in rheumatology practice.
Post hoc analysis showed a positive correlation (r = 0.58,
p < 0.0001) between the age of RAO and HDI by country for
the years 2010 to 2014, with a coefficient of determination
(R2) of 0.33. When the HDI was adjusted for inequality (year
2014), the positive correlation became stronger (r = 0.71,
p < 0.01), with an R2 of 0.50.
Discussion
Despite the importance of age of RAO as an outcome
predictor, data on its variability in different populations
are scarce and limited to specific geographical regions.
In this proof-of-concept study, the age of RAO was
evaluated in different regions of the world and its var-
iability was analyzed per latitude gradients, as these are
used as surrogates of environmental factors to posit hy-
potheses for further study.
Table 2 Mean age of onset of rheumatoid arthritis (RA) by region (longitude), according to latitude
Regions by longitudes (longitude range) and participating countries
Region 1 (30° W to 134° W) Region 2 (29° W to 104° E) Region 3 (105° E to 180° E)
Argentina, Brazil, Canada, Chile, Colombia,
Ecuador, Honduras, Mexico, Panama,
Paraguay, Peru, Venezuela
Burkina Faso, Finland, France, Kenya,
Netherlands, Nigeria, Norway, Saudi Arabia,
South Africa, Spain, Sweden, Ghana, Russia,
Egypt, Algeria, Germany, Switzerland, Qatar,
Bangladesh, Iran, Singapore, Thailand, India,
Nepal
China, Japan, New Zealand,
Philippines, Australia
Latitude (range) Patients N= RA age of onset
Mean ± SD (95% CI)
Patients N= RA Age of onset
Mean ± SD (95% CI)
Patients N= RA age of onset
Mean ± SD (95% CI)
1 (>40° S) 57 41 ± 13 (38 to 44.5) – – 39 51.5 ± 14
47 to 56
2 (31°–40° S) 339 45 ± 14 (44 to 47) 57 46 ± 12
43 to 49
77 46.5 ± 14
43 to 50
3 (21°–30° S) 156 44 ± 13 (42 to 46) 38 43 ± 13
39 to 48
19 57 ± 11
51 to 62
4 (11°–20° S) 80 45 ± 14.5 (41.5 to 48) – – – –
5 (1°–10° S) 118 44 ± 13 (41 to 46) 20 37.5 ± 11
32 to 43
– –
6 (0°–9° N) 79 44 ± 14 (41 to 47) 79 44 ± 15
41 to 48
– –
7 (10°–19° N) 98 41 ± 13 (38 to 43) 139 44 ± 13
42 to 46.5
79 47 ± 14
44 to 50
8 (20°–29° N) 76 38 ± 11.5 (35 to 40) 274 39.5 ± 12
38 to 41
39 46 ± 13
42 to 50.5
9 (30°–39° N) – – 153 42 ± 15
40 to 44.5
40 47 ± 14
42 to 51
10 (40°–49° N) 20 52.5 ± 16 (45 to 60) 133 47 ± 14
45 to 49
– –
11 (>50° N) 39 46 ± 15 (41 to 51) 233 48 ± 15
46 to 50
– –
Total 1062 44 ± 14 (43 to 45) 1126 44 ± 14
43 to 45
293 48 ± 14
46 to 49.5
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Our first important finding is that, in general, RA is
not a disease of older adulthood. Based on the sample
size of 2481 patients from 41 countries and the narrow
95% CI of the mean, we believe that our data are quite
robust. The fact that half of RA patients worldwide
have disease onset at a young age has several implica-
tions. First, RA may have a greater individual and fa-
milial impact than previously believed because its onset
is before individuals reach their peak life roles. Second,
the general perception that RA occurs mainly in older
adulthood, which is based on older data from developed
northern countries [1], may mislead local policy makers
when allocating resources and developing health care
strategies for a disease that can last as long as 40 years
in many cases. Third, it is possible that the age of RAO
has changed over the past five decades, together with
temporal trends in the occurrence of RA [1, 4–6,
20–23].
Our second finding is that the age of RAO is significantly
different along latitude gradients. We have shown that at lati-
tudes around the Tropic of Cancer (latitude codes 8 and 9), RA
starts at a younger age, with a higher proportion of patients
developing the disease before age 36 years as compared with
northern and southern latitudes. When analyzed by region
(longitudes), similar trends were observed for region 1.
Region 2 also showed significant trends, but the data are not
as robust as for the Americas. Region 3 lacked data at several
latitudes, and the broad 95%CI observed for the available data
indicates a possible type II error. However, multiple linear
regression models showed that RA starts at a significantly
Table 3 Frequency distribution of age groups for onset of rheumatoid arthritis by region (longitude), according to latitude
Latitude codesa
1 2 3 4 5 6 7 8 9 10 11
Longitudes
Region 1 (30° W to 134° W)
Age groups, n (%)b
16–25 years 4 (7) 24 (7) 15 (10) 8 (10) 12 (10) 8 (10) 12 (12) 9 (12) – 1 (5) 3 (8)
26–35 years 18 (32) 60 (18) 25 (16) 14 (17.5) 19 (16) 14 (18) 23 (23.5) 25 (33) – 3 (15) 7 (18)
36–45 years 12 (21) 85 (25) 39 (25) 16 (20) 27 (23) 21 (27) 23 (23.5) 20 (26) – 2 (10) 9 (23)
46–55 years 13 (23) 79 (23) 40 (26) 22 (27.5) 36 (30.5) 19 (24) 29 (30) 16 (21) – 5 (25) 6 (15)
56–65 years 8 (14) 64 (19) 27 (17) 12 (15) 18 (15) 12 (15) 6 (6) 5 (7) – 5 (25) 10 (26)
>65 years 2 (3.5) 27 (8) 10 (6) 8 (10) 6 (5) 5 (6) 5 (5) 1 (1) – 4 (20) 4 (10)
Total 57 339 156 80 118 79 98 76 – 20 39
Region 2 (29° W to 104° E)
Age groups, n (%)b
16–25 years – 4 (7) 4 (10.5) – 3 (15) 13 (16.5) 14 (10) 31 (11) 16 (10.5) 5 (4) 15 (6)
26–35 years – 5 (9) 7 (18) – 5 (25) 6 (8) 20 (14) 71 (26) 41 (27) 28 (21) 37 (16)
36–45 years – 19 (33) 8 (21) – 7 (35) 19 (24) 27 (19) 78 (28.5) 32 (21) 28 (21) 43 (18.5)
46–55 years – 19 (33) 12 (32) – 4 (20) 22 (28) 51 (37) 70 (25.5) 37 (24) 32 (24) 49 (21)
56–65 years – 7 (12) 6 (16) – 1 (5) 12 (15) 24 (17) 18 (7) 14 (9) 25 (19) 53 (23)
>65 years – 3 (5) 1 (3) – 0 (0) 7 (9) 3 (2) 6 (2) 13 (8.5) 15 (11) 36 (15.5)
Total – 57 38 – 20 79 139 274 153 133 233
Region 3 (105° E to 180° E)
Age groups, n (%)b
16–25 years 0 (0) 4 (5) 0 (0) – – – 7 (9) 1 (3) 2 (5) – –
26–35 years 4 (10) 15 (19.5) 0 (0) – – – 11 (14) 9 (23) 7 (17.5) – –
36–45 years 11 (28) 21 (27) 3 (16) – – – 11 (14) 6 (15) 11 (27.5) – –
46–55 years 10 (26) 15 (19.5) 6 (32) – – – 27 (34) 13 (33) 9 (22.5) – –
56–65 years 5 (13) 13 (17) 4 (21) – – – 19 (24) 6 (15) 8 (20) – –
>65 years 9 (23) 9 (12) 6 (32) – – – 4 (5) 4 (10) 3 (7.5) – –
Total 39 77 19 – – – 79 39 40 – –
a Latitude codes: 1 = >40° S; 2 = 31° S–40° S; 3 = 21° S–30° S; 4 = 11° S–20° S; 5 = 1° S–10° S; 6 = 0°–9°N; 7 = 10° N–19° N; 8 = 20° N–29° N; 9 = 30°
N–39° N; 10 = 40° N–49° N; and 11 = >50° N
bRounded numbers
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younger age among females; in patients from latitude codes 5,
7, 8, and 9; and in those from countries in the Western
Hemisphere (west of the Greenwich parallel).
Although we found no similar reports with which to
compare our results, these are in concert with other
studies conducted at regional level. In 2007, our group
reported that the mean age of RAO was significantly
younger among Mexicans than among Canadians [15],
with figures similar to those reported here. Abdel-Nasser
et al. [1] reported that Egyptian patients, especially
women, had a significantly younger age of RAO than
Dutch patients. Studies from India and Pakistan have a
higher RA prevalence in the age groups of 25–29 years
[24] and 16–29 years [25], respectively. Studies from
the USA have found that the incidence of RA varies
by geographic coordinates [26, 27].
Therefore, it seems plausible that latitude gradients play a
major role in triggering those mechanisms responsible for RA
initiation among genetically predisposed subjects. We posit
that this happens because of two characteristics that are shared
among countries located near the Tropic of Cancer, which
may differentiate them from nations at northern latitudes: the
developmental status of these countries (developing countries
around the Tropic of Cancer versus developed northern na-
tions) and the latitude gradient per se.
Post hoc analysis showed a significant relationship be-
tween the age of RAO and countries’ HDI, which became
even stronger when adjusted for inequality. Developmental
status takes into account life expectancy, education, per capita
income, and inequality. These variables can in turn act as
surrogates for population health, lifestyle, environmental pol-
lutants, and exposure to infections. Therefore, air pollution,
local environmental policies, social inequalities, the age of
exposure to infections and how they are treated, changes in
the microbiome because of infection or seasonal variation in
diet [28], oral contraceptive use, age at first pregnancy, and
breastfeeding practices may be related to differences between
developing and developed countries. For instance, air pollu-
tion—a mixture of suspended particulate matter mainly from
vehicular traffic, industry, stationary fuel burners, and solid
fuel combustion—has recently been found to be associated
with RA [29]. A study in Sweden found that the risk of de-
veloping RAwas increased with exposure to gaseous pollut-
ants (NO2 and SO2) in the 10th year before disease onset [30].
Lower socioeconomic status has been associated with RA
[31], and there is an increased risk of exposure to atmospheric
Table 4 Stepwise linear
regression, variables associated
with age of onset of rheumatoid
arthritis
Variable Univariable β
coefficient
95% CI)
p value Multivariable β
coefficient
(95% CI)
p value
Sex (female) −4.4 (−5.8; −2.9) <0.01 −3.9 (−5.4; −2.6) <0.01
Latitude codea
1 (>40° S) −2.7 (−5.9; 0.5) 0.09 −1.4 (−4.7; 1.8) 0.37
2 (31° to 40° S) −2.3 (−4.4; −0.3) 0.02 −0.9 (−3.1; 1.3) 0.42
3 (21° to 30° S) −2.9 (−5.5; −0.5) 0.02 −1.5 (−4.1; 1.1) 0.25
4 (11° to 20° S) −3.3 (−6.7; 0.1) 0.05 −1.2 (−4.7; 2.4) 0.53
5 (1° to 10° S) −5.1 (−7.9; −2.2) <0.01 −3.2 (−6.2; −0.3) 0.03
6 (0° to 9° N) −3.8 (−6.5; −1.1) <0.01 −2.4 (−5.2; 0.3) 0.08
7 (10° to 19° N) −4.2 (−6.4; −1.9) <0.01 −3.3 (−5.5; −1.0) <0.01
8 (20° to 29° N) −8.2 (−10.3; −6.0) <0.01 −7.6 (−9.7; −5.4) <0.01
9 (30° to 39° N) −4.9 (−7.5; −2.4) <0.01 −4.3 (−6.8; −1.8) <0.01
10 (40° to 49° N) −0.4 (−3.2; 2.3) 0.8 −0.0 (−2.7; 2.7) 0.99
Cities above the equator −1.1 (−2.3; −0.02) 0.04 *
Longitude regionsb
Europe, Africa, West Asiac 1.9 (0.1; 3.6) 0.04 **
Americas (30° W to 134° W) −1.6 (−3.2; 0.07) 0.06 **
Western citiesd −0.9 (−2.0; 0.2) 0.10 −1.6 (−2.9 ; −0.3) 0.01
a Group 11 (>50° N) is the referent group
b East Asia, Australia, and New Zealand (105° E to 180° E) is the referent group
c Europe, Africa, Western Asia; 29° W to 104° E
d Starting from the Greenwich parallel
*Nonsignificant in the second step
**Nonsignificant in the third step
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pollution and greater smoking consumption compared with
individuals at higher income levels [32, 33]. A variable also
to consider is oral contraceptive use, which may delay the
onset of RA [34] and have a protective effect [35]. Use of oral
contraceptives is less common at an early age in developing
countries than in developed ones [36]. Having more than one
pregnancy, young age at first pregnancy, and breastfeeding
patterns are other possible factors [37–39]. A delay in the
age of RAO in developed countries may be related to an in-
creased tendency to postpone first pregnancies or a tendency
not to breastfeed [40]. Exposure to infections may have a dual
effect on the initiation of RA in susceptible individuals. Some
infections may produce a protective effect [41, 42], whereas
others, such as periodontal disease, may increase the risk of
triggering RA [31]. Hence, exposure to specific infectious
agents and how they are treated, with consequent changes in
the microbiome [43], may be related to socioeconomic status,
health care characteristics, and inequality, which may in turn
be related to a country’s developmental status.
Several of these variables can be modified by non-
medical means that depend more on public health mea-
sures than on pharmacologic interventions. If our hy-
pothesis is correct, the age of RAO could be modified
to affect fewer years in the lives of RA patients from
developing countries, analogous to the decline in infec-
tious diseases during the 19th and 20th centuries before
the extended use of antibiotics, thereby reducing disease
burden and health care costs [44].
The second characteristic that differentiates countries
around the Tropic of Cancer from those at northern latitudes
is the gradient of latitudes where countries are located. The
incidence and periodicity of RA have been found to be related
to increasing geographic latitudes, which determine the mag-
nitude of exposure to variables such as solar cycles, auroral
electrojets, extreme ultraviolet radiation, substorms, and mag-
netic field perturbations [45]. Unfortunately, these variables
have only been studied in limited geographic areas over short
time spans. Future studies with larger data sets that cover
several countries and organized by geomagnetic and geo-
graphic coordinates would be necessary, to assess the biologic
disturbance and magnitude that these variables may cause [46]
on the incidence and age of RAO.
We chose a proof-of-concept study for feasibility reasons;
however, this design has inherent limitations such as the fact
that chance (random), bias, and confounders cannot be con-
trolled. Our approach to decrease issues of RA ascertainment
and selection bias included the recruitment of rheumatologists
listed in rheumatology association registers as well as their self-
reporting of board certification and that they had patients with
RA under their care. Instructions for determining patient age of
RAOwere clearly stated, and participants were not informed of
the primary aim of the study at the time of data collection. The
wide standard deviation in the mean age of RAO observed in
each data set suggests that participants maintained a typical
rheumatology practice. Unfortunately, it was possible to assess
intracity consistency in only one third of participating cities,
and inconsistencies were found in some of them. Chance is
the most viable explanation based on the small sample of pa-
tients that we requested of each rheumatologist, the broad 95%
CI of each data set, and the nonsignificance of other variables
such as length or type of practice.
Intracountry consistency could be assessed for nearly half
of participating countries, but some significant differences
were observed. We retrieved the mean age of RAO reported
in other studies (referent studies), to gain some insight into
how much of our data from these countries are different from
those reported previously, although the definitions of age of
onset in these referent studies were different from ours. Mean
ages of RAO in referent studies fromBrazil (44.9 ± 14.5 years)
[47] and Australia (49.6 ± 11 years) [48] were similar to our
data from these countries; we did not find any published data
from Ecuador. However, the main limitation of our study lies
in the 11 (27%) countries where only one rheumatologist par-
ticipated. Referent studies from Switzerland (mean age of
RAO 51.5 years) [49], Japan (49 years) [50], Kenya
(41 ± 17 years) [51], Nigeria (42 years) [52], Sweden
(58 ± 18 years) [14], Russia (53 years) [53], Colombia
(44 ± 12 years) [54], Burkina Faso (35 years) [55], and Iran
(41 ± 13 years) [56] reported figures similar to ours. We did
not find referent studies from Ghana or Panama.
In summary, RA often begins at an early age and its onset
varies across latitudes throughout the world. From this obser-
vation, it can be hypothesized that countries’ developmental
status and location influence the age of RAO. These features
warrant further studies on the precise magnitude of this phe-
nomenon and the possible causality of diverse factors such as
pollution, pregnancy-related patterns, and infection expo-
sures, all adjusted for inequality, as well as atmospheric vari-
ables adjusted by geographical and geomagnetic coordinates.
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